Oct. 28, 2014, 7:31 AM
- Sanofi (NYSE:SNY) (OTCQB:SNYNF) is off 8% premarket on moderately higher volume in response to its announcement that sales of its diabetes products will be flat next year due to increased competition in the U.S. CEO Chris Viehbacher says that the firm had to discount Lantus last quarter in order to get on U.S. drug benefit managers' reimbursement lists along with its competitors including Novo Nordisk A/S (NYSE:NVO).
Oct. 6, 2014, 11:41 AM
- Shares of micro cap Unilife (NASDAQ:UNIS) (OTC:UNISZ) jump 25% on a 6x surge in volume in response to its announcement of a long-term supply agreement with Sanofi (NYSE:SNY) (OTCQB:SNYNF).
- Under the terms of the agreement, Unilife will be the sole provider of cartridge-based wearable injectors for all of Sanofi's applicable large-dose volume drugs, excluding insulins, for a minimum of 15 years. Sanofi will have non-exclusive access to the wearable injectable technology and be allowed to make the technology available to its partners for use with applicable molecules under joint collaborations. Unilife maintains the right to enter into supply agreements with other pharma companies contingent on the preservation of Sanofi's non-exclusive access. Sanofi has the right to extend the agreement for additional periods.
- Unilife expects to receive ~$50M from the partnership, which includes an undisclosed upfront payment.
- Sanofi has five to ten molecules that will be delivered via wearable injectors.
SNYNF vs. ETF Alternatives
Other News & PR